Mechanistically, RBM4 disrupts the LKB1/MO25/STRAD complex and recruits TRIM26 to promote LKB1 degradation, rendering ESCC cells susceptible to glutaminase inhibitor, CB-839, and offering a novel approach for ESCC targeted therapy (Fig. 8). This evidence concerns the gene STRADA and esophageal squamous cell carcinoma.